Spots Global Cancer Trial Database for Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Official Title: Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity
Study ID: NCT01779882
Study Description
Brief Summary: The aim of this study is to test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital, Basel, Basel, , Switzerland
University Hospital Geneva, Geneva, , Switzerland
University Hospital Zurich, Zurich, , Switzerland
Contact Details
Name: Nathan Cantoni, MD
Affiliation: Kantonsspital Aarau, Switzerland
Role: STUDY_CHAIR
Name: Sabine Gerull, MD
Affiliation: University Hospital, Basel, Switzerland
Role: PRINCIPAL_INVESTIGATOR
Name: Gayathri Nair, MD
Affiliation: University Hospital, Zürich
Role: PRINCIPAL_INVESTIGATOR
Name: Yves Chalandon, MD
Affiliation: University Hospital Geneva, Switzerland
Role: PRINCIPAL_INVESTIGATOR
Name: Jakob Passweg, MD
Affiliation: University Hospital, Basel, Switzerland
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
